Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Uterine Cervical Neoplasms 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Advanced Solid Tumors 4Lung Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Solid Tumor 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Tumor, Unspecified, Adult 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Metastatic Urothelial Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Kidney Neoplasms 1Erythrocytosis, Familial, 4 1Endometrial Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 40Gemcitabine 37Cisplatin 28Carboplatin 17enfortumab vedotin 15Nivolumab 15Mitomycin 14atezolizumab 13avelumab 12Docetaxel 10vinflunine 95-aminolevulinic acid hexyl ester 9apaziquone 8Paclitaxel 8BCG Vaccine 7durvalumab 6Fluorouracil 6Cystectomy 6sacituzumab govitecan 4Surgical Procedures, Operative 4Drug Therapy 4vofatamab 3valrubicin 3tisotumab vedotin 3erdafitinib 3cemiplimab 3belinostat 3Therapeutic Uses 3Ramucirumab 3Cystoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Urinary Bladder Neoplasms × zimberelimab × Clear all
NCT05891171 2026-06-05

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
48 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡